Literature DB >> 18384178

Metabolic viability assessment of cystic echinococcosis using high-field 1H MRS of cyst contents.

Waldemar Hosch1, Thomas Junghanss, Marija Stojkovic, Enrico Brunetti, Tobias Heye, Günter W Kauffmann, William E Hull.   

Abstract

Cystic echinococcosis is a worldwide disease caused by larval stages of the parasite Echinococcus granulosus (canine tapeworm). In clinical practice, staging of cyst development by ultrasonography (US) has allowed treatment options to be tailored to individual patient needs. However, the empirical correlation between cyst morphology and parasite viability is not always dependable and has, until now, required confirmation by invasive assessment of cyst content by light microscopy (LM), for example. Alternatively, high-field 1H MRS may be used to examine cyst fluid ex vivo and prepare detailed quantitative metabolite profiles, enabling a multivariate metabolomics approach to cyst staging. One-dimensional and two-dimensional 1H and 1H/13C MRS at 600 MHz (14.1 T) was used to analyze 50 cyst aspirates of various US and LM classes. MR parameters and concentrations relative to internal valine were determined for 44 metabolites and four substance classes. The high concentrations of succinate, fumarate, malate, acetate, alanine, and lactate found in earlier studies of viable cysts were confirmed, and additional metabolites such as myo-inositol, sorbitol, 1,5-anhydro-D-glucitol, betaine, and 2-hydroxyisovalerate were identified. Data analysis and cyst classification were performed using univariate (succinate), bivariate (succinate vs fumarate), and multivariate partial least squares discriminant analysis (PSL-DA) methods (with up to 48 metabolite variables). Metabolic classification of 23 viable and 18 nonviable cysts on the basis of succinate alone agreed with LM results. However, for seven samples, LM and MRS gave opposing results. Reclassification of these samples and two unclassified samples by PLS-DA prediction techniques led to a set of 50 samples that could be completely separated into viable and nonviable MRS classes with no overlap, using as few as nine variables: succinate, formate, malate, 2-hydroxyisovalerate, acetate, total protein content, 1,5-anhydro-D-glucitol, alanine, and betaine. Thus, future noninvasive in vivo applications of MRS would appear promising. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18384178     DOI: 10.1002/nbm.1252

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  37 in total

1.  Prevalence and Risk Factors for Human Cystic Echinococcosis in the Cusco Region of the Peruvian Highlands Diagnosed Using Focused Abdominal Ultrasound.

Authors:  Francesca Tamarozzi; Amy Hou; Maria Luisa Morales; Maria Teresa Giordani; Freddy Vilca; Karen Mozo; Ruben Bascope; A Clinton White; Enrico Brunetti; Lin Chen; Miguel M Cabada
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 2.  Metabolomics: moving to the clinic.

Authors:  Anders Nordström; Rolf Lewensohn
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-28       Impact factor: 4.147

3.  [Cardiac manifestations of tropical diseases].

Authors:  C Kraef; M Ramharter
Journal:  Herz       Date:  2019-02       Impact factor: 1.443

4.  Expert Reliability for the World Health Organization Standardized Ultrasound Classification of Cystic Echinococcosis.

Authors:  Nadia Solomon; Paul J Fields; Francesca Tamarozzi; Enrico Brunetti; Calum N L Macpherson
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

Review 5.  Cystic echinococcosis of the liver: A primer for hepatologists.

Authors:  Francesca Rinaldi; Enrico Brunetti; Andreas Neumayr; Marcello Maestri; Samuel Goblirsch; Francesca Tamarozzi
Journal:  World J Hepatol       Date:  2014-05-27

6.  Role of microRNAs in host defense against Echinococcus granulosus infection: a preliminary assessment.

Authors:  Mara Mariconti; Ambra Vola; Tommaso Manciulli; Francesca Genco; Raffaella Lissandrin; Valeria Meroni; Mara Rosenzvit; Francesca Tamarozzi; Enrico Brunetti
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

Review 7.  Hepatic echinococcosis: clinical and therapeutic aspects.

Authors:  Giuseppe Nunnari; Marilia R Pinzone; Salvatore Gruttadauria; Benedetto M Celesia; Giordano Madeddu; Giulia Malaguarnera; Piero Pavone; Alessandro Cappellani; Bruno Cacopardo
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

8.  Efficacy and safety of PAIR for cystic echinococcosis: experience on a large series of patients from Bulgaria.

Authors:  Branimir Golemanov; Nikola Grigorov; Rumiana Mitova; Jordan Genov; Dimitar Vuchev; Francesca Tamarozzi; Enrico Brunetti
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

9.  Immunoblotting with human native antigen shows stage-related sensitivity in the serodiagnosis of hepatic cystic echinococcosis.

Authors:  Mara Mariconti; Chiara Bazzocchi; Francesca Tamarozzi; Valeria Meroni; Francesca Genco; Roberta Maserati; Enrico Brunetti
Journal:  Am J Trop Med Hyg       Date:  2013-12-02       Impact factor: 2.345

10.  Factors Influencing the Serological Response in Hepatic Echinococcus granulosus Infection.

Authors:  Raffaella Lissandrin; Francesca Tamarozzi; Luca Piccoli; Carmine Tinelli; Annalisa De Silvestri; Mara Mariconti; Valeria Meroni; Francesca Genco; Enrico Brunetti
Journal:  Am J Trop Med Hyg       Date:  2015-10-26       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.